HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32

Immunobiology

Volumn 218, Issue 4, 2013, Pages 543-547

  Ballana, Ester ^a   Riveira Munoz, Eva ^a   Pou, Christian ^a   Bach, Vanessa ^a   Parera, Mariona ^a   Noguera, Marc ^a   Santos, José R ^a   Badia, Roger ^a   Casadellà, Maria ^a   Clotet, Bonaventura ^a   Paredes, Roger ^a   Martínez, Miguel Angel ^a   Brander, Christian ^a,b   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

CCR5 32; Disease progression; HLA; Treatment outcome

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DIDANOSINE; HLA A 2402 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B 5701 ANTIGEN; HLA B ANTIGEN; LOPINAVIR; RITONAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ALLELE; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; DISEASE COURSE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS ISOLATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLELES; BASE SEQUENCE; FEMALE; HIV-1; HLA-A24 ANTIGEN; HLA-B ANTIGENS; HUMANS; IMMUNITY, CELLULAR; MALE; RECEPTORS, CCR5; SEQUENCE DELETION; T-LYMPHOCYTES;

EID: 84875233718     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.06.012     Document Type: Article

References (29)

1. Este J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
2. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
3. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res. 2010, 85:91-100.
4. Balotta C., Bagnarelli P., Violin M., Ridolfo A.L., Zhou D., Berlusconi A., Corvasce S., Corbellino M., Clementi M., Clerici M., Moroni M., Galli M. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997, 11:F67-F71.
5. Heiken H., Becker S., Bastisch I., Schmidt R.E. HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32. AIDS 1999, 13:529-530.
6. Kuipers H., Workman C., Dyer W., Geczy A., Sullivan J., Oelrichs R. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A allele. AIDS 1999, 13:433-434.
7. Stewart G.J., Ashton L.J., Biti R.A., Ffrench R.A., Bennetts B.H., Newcombe N.R., Benson E.M., Carr A., Cooper D.A., Kaldor J.M. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian long-term non-progressor study group. AIDS 1997, 11:1833-1838.
8. Gorry P.R., Zhang C., Wu S., Kunstman K., Trachtenberg E., Phair J., Wolinsky S., Gabuzda D. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002, 359:1832-1834.
9. Gray L., Churchill M.J., Keane N., Sterjovski J., Ellett A.M., Purcell D.F., Poumbourios P., Kol C., Wang B., Saksena N.K., Wesselingh S.L., Price P., French M., Gabuzda D., Gorry P.R. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J. Virol. 2006, 80:3684-3691.
10. Ballana E., Esté J.A. HIV-1 infection and CCR5 Delta 32 homozygosis. Future Virology 2012, 7:659-678.
11. Cheng-Mayer C., Seto D., Tateno M., Levy J.A. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988, 240:80-82.
12. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 1992, 66:1354-1360.
13. Ballana E., Senserrich J., Pauls E., Faner R., Mercader E., Uyttebroeck F., Palou E., Mena M.P., Grau E., Clotet B., Ruiz L., Telenti A., Ciuffi A., Esté J.A. Zinc ribbon domain-containing 1 (ZNRD1) is a host cellular factor influencing HIV-1 replication and disease progression. Clin. Infect. Dis. 2010, 50:1022-1032.
14. Carrington M., Walker B.D. Immunogenetics of spontaneous control of HIV. Annu. Rev. Med. 2012, 63:131-145.
15. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 2000, 97:2709-2714.
16. Ballana E., Ruiz-de Andres A., Mothe B., Ramirez de Arellano E., Aguilar F., Badia R., Grau E., Clotet B., del Val M., Brander C., Este J. Differential prevalence of the HLA-C-35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. Immunobiology 2012, 10.1016/j.imbio.2011.12.012.
17. Tsibris A.M.N., Korber B., Arnaout R., Russ C., Lo C.-C., Leitner T., Gaschen B., Theiler J., Paredes R., Su Z., Hughes M.D., Gulick R.M., Greaves W., Coakley E., Flexner C., Nusbaum C., Kuritzkes D.R. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009, 4:e5683.
18. Fernandez G., Llano A., Esgleas M., Clotet B., Este J.A., Martinez M.A. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing CXCR4-tropic viruses. J. Gen. Virol. 2006, 87:1285-1294.
19. Gonzalez E., Ballana E., Clotet B., Estã© J.A. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 2011, 25:1557-1583.
20. Mothe B., Llano A., Ibarrondo J., Zamarreno J., Schiaulini M., Miranda C., Ruiz-Riol M., Berger C.T., Herrero M.J., Palou E., Plana M., Rolland M., Khatri A., Heckerman D., Pereyra F., Walker B.D., Weiner D., Paredes R., Clotet B., Felber B.K., Pavlakis G.N., Mullins J.I., Brander C. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 2012, 7:e29717.
21. Frahm N., Korber B.T., Adams C.M., Szinger J.J., Draenert R., Addo M.M., Feeney M.E., Yusim K., Sango K., Brown N.V., SenGupta D., Piechocka-Trocha A., Simonis T., Marincola F.M., Wurcel A.G., Stone D.R., Russell C.J., Adolf P., Cohen D., Roach T., StJohn A., Khatri A., Davis K., Mullins J., Goulder P.J., Walker B.D., Brander C. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 2004, 78:2187-2200.
22. Yusim K.K.B., Brander C., Haynes B.F., Koup R., Moore J.P., Walker B.D., Watkins D.I. HIV Molecular Immunology 2009 2009, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, LA-UR 09-05941.
23. Montefiori D.C., Altfeld M., Lee P.K., Bilska M., Zhou J., Johnston M.N., Gao F., Walker B.D., Rosenberg E.S. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J. Immunol. 2003, 170:3906-3914.
24. Li J., Chen X., Huang J., Jiang S., Chen Y.H. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. Immunobiology 2009, 214:51-60.
25. Gonzalez-Ortega E., Ballana E., Badia R., Clotet B., Este J.A. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. Antivir. Res. 2011, 92:479-483.
26. Sedaghat A.R., Rastegar D.A., O'Connell K.A., Dinoso J.B., Wilke C.O., Blankson J.N. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin. Infect. Dis. 2009, 49:1763-1766.
27. Kamya P., Boulet S., Tsoukas C.M., Routy J.P., Thomas R., Cote P., Boulassel M.R., Baril J.G., Kovacs C., Migueles S.A., Connors M., Suscovich T.J., Brander C., Tremblay C.L., Bernard N. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J. Virol. 2011, 85:5949-5960.
28. Kaufmann D.E., Lichterfeld M., Altfeld M., Addo M.M., Johnston M.N., Lee P.K., Wagner B.S., Kalife E.T., Strick D., Rosenberg E.S., Walker B.D. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004, 1:e36.
29. Salgado M., Simon A., Sanz-Minguela B., Rallon N.I., Lopez M., Vicario J.L., Benito J.M., Rodes B. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J. Acquir. Immune Defic. Syndr. 2011, 56:300-305.